


Global AIDS Spending Flatlined...



Past/Current Spending

NOTES: Includes funding in support of AIDS treatment, prevention and care. Differs from White House figures because does not include NIH research or non-PEPFAR bilateral TB, which are not included as part of the \$39b of activities within Lantos-Hyde. (See page 2)

US AIDS FUNDING (\$millions)	Fy04	FY05	FY06	FY07	FY08	FY09	Fy10	FY11 (P Req)
Global Fund (state)	398	248	446	626	546	600	750	700
Global Fund (HHS)	149	99	99	99	295	300	300	300
Global Fund Total	547	435	545	742	841	900	1050	1000
CDC Global HIV	143	124	123	121	119	119	119	118
USAID Global HIV	607	434	414	346	372	350	350	350
PEPFAR-State (& UNAIDS)	488	1374	1777	2869	4117	4559	4609	4800
Other (DOD, DOL, etc)	163	9	5	2	9	8	10	0
Bilateral AIDS Total	1401	1941	2319	3338	4617	5036	5088	5268
Total AIDS (Bilateral + 50% Global Fund)	1675	2159	2592	3709	5038	5486	5613	5768

Scale up to reach PEPFAR Authorization Levels

The Lantos-Hyde Act includes \$48 billion: \$4b for TB, \$5b for Malaria, and \$39b for AIDS. Roughly half of Global Fund financing each year goes to AIDS and therefore the total AIDS number calculated below includes that portion. Below is a projection that demonstrates a path to scale up to reach \$39b for AIDS: the president's request of 2% increases will not reach the promised levels.

Lantos Hyde (\$billions)	FY08 (base)	FY09 (enacted)	FY10 (enacted)	FY11 (L-H)	VS FY11 (Pres Req)	FY12 (L-H)	FY13 (L-H)	Total AIDS:
Bilateral AIDS Total	4.6	5.036	5.088	7.5	5.268	8.25	9	
Global Fund	0.85	0.9	1.05	1.75	1.00	2.25	2.5	
50% of GF	0.425	0.45	0.525	0.875	0.50	1.125	1.25	
AIDS Total (Bilateral + 50% GF)	5.025	5.486	5.613	8.375	5.768	9.375	10.25	\$39 billion

How do the administration numbers compare?

Administration reports for AIDS and PEPFAR funding levels have differed based on source, but all have included various programs that are not part of the *Lantos-Hyde* authorization or PEPFAR program including:

- Bilateral Tuberculosis—USAID & other non-AIDS related TB, which has a separate *Lantos-Hyde* authorization for a total of \$4 billion over 5 years and is administered outside PEPFAR.
- NIH Globally-focused research—very important but not authorized under *Lantos-Hyde* activities. Since the funding does not go directly to treatment, care and prevention scale up it is not part of reaching L-H authorized levels.
- The Global Fund—an essential and underfunded priority, specifically authorized in *Lantos-Hyde* as additional to the targets (and funding) for bilateral programs.

To understand what is available for bilateral programs these must be subtracted, to reach a total of **\$5.268 b in FY 2011**. (We note that this also includes other, smaller non-bilateral program elements.)

Also included in these numbers is \$100 million for the “GHI Plus Fund” which has not yet been defined. It is not clear how/whether this will go to scale up AIDS treatment, care, and prevention and, if so, why it is being pulled out and administered differently. Without that funding the total increase is \$80 million.

	FY 10 (enacted)	FY11 (pres req)	Change	% Change
PEPFAR/OGAC number:	6.838	6.99	0.152	2.2%
-Bilateral TB	0.246	0.251	0.005	2.0%
White House AIDS Figure	6.592	6.739	0.147	2.2%
-Global Fund	1.05	1	-0.05	-4.8%
-NIH	0.454	0.471	0.017	3.7%
Bilateral/AIDS Programs	5.088	5.268	0.18	3.5%
-Less GHI Fund	0	0.1	-0.08	-1.6%
Balance	5.088	5.168	-0.08	-1.6%

Contact: Matthew Kavanagh, Health GAP matthew@healthgap.org, 202 355-6343